With the pricing ball in Gilead’s court, ICER offers some parameters on how it can be played — analyst sees at least ‘$1B in theory’

When asked directly on Gilead?s recent earnings call whether the company expects to profit from remdesivir ? the only antiviral to have generated positive clinical data on a randomized, placebo-controlled trial and earned Anthony Fauci?s endorsement as a standard-of-care ? Daniel O?Day was careful not to commit. ?(T)here is no…

Click to view original post